Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

86.60 1.50 −1.70%
Market cap
$50.8B
P/E
49.8×
Fwd P/E
30.7×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
2,963.70 3,435.30 3,722.80 4,348.00 4,386.30 5,232.50 4,464.00 5,010.00 5,439.50 6,067.60
Revenue Growth
18.85% 15.91% 8.37% 16.79% 0.88% 19.29% (14.69%) 12.23% 8.57% 11.55%
Gross Profit
2,166.30 2,560.00 2,783.40 3,233.60 3,305.70 3,983.60 3,740.30 4,031.60 4,322.00 4,733.40
Operating Income
783.80 1,089.40 748.20 1,146.80 897.60 1,690.30 1,498.40 1,308.90 1,378.70 1,264.20
EBT
737.90 1,034.90 761.40 1,166.50 916.70 1,702.00 1,519.50 1,372.40 1,548.10 1,272.90
Income after Tax
569.50 583.60 722.20 1,046.90 823.40 1,503.10 1,324.00 1,220.00 1,396.00 1,056.00
Net Income Common
569.50 583.60 722.20 1,046.90 823.40 1,503.10 1,521.90 1,402.40 4,174.60 1,073.50
EPS (Diluted)
0.87 0.96 1.13 1.64 1.30 2.38 2.44 2.30 6.97 1.83
Shares (Diluted, Weighted)
653.40 647.70 640.90 636.70 631.90 631.20 624.20 609.40 599.30 585.80
Gross Margin
73.09% 74.52% 74.77% 74.37% 75.36% 76.13% 83.79% 80.47% 79.46% 78.01%
EBIT Margin
26.45% 31.71% 20.10% 26.38% 20.46% 32.30% 33.57% 26.13% 25.35% 20.84%
Net Profit Margin
19.22% 16.99% 19.40% 24.08% 18.77% 28.73% 34.09% 27.99% 76.75% 17.69%
Free Cash Flow Margin
16.43% 24.02% 18.40% 20.80% 14.75% 26.80% 21.36% 12.56% 4.78% 22.00%
EBITDA
855.00 1,171.30 825.60 1,236.10 1,004.80 1,825.10 1,638.00 1,453.80 1,533.90 1,420.80
EBIT
783.80 1,089.40 748.20 1,146.80 897.60 1,690.30 1,498.40 1,308.90 1,378.70 1,264.20

Show all line items

In millions of $ except per-share values · columns are period end dates